BlackRock Fund Advisors boosted its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 6.0% during the third quarter, Holdings Channel reports. The institutional investor owned 810,238 shares of the biopharmaceutical company’s stock after buying an additional 45,653 shares during the period. BlackRock Fund Advisors owned about 2.13% of Agios Pharmaceuticals worth $42,797,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in AGIO. DIAM Co. Ltd. raised its stake in shares of Agios Pharmaceuticals by 110.8% in the third quarter. DIAM Co. Ltd. now owns 71,030 shares of the biopharmaceutical company’s stock valued at $3,680,000 after buying an additional 37,336 shares in the last quarter. Swiss National Bank raised its stake in shares of Agios Pharmaceuticals by 12.6% in the third quarter. Swiss National Bank now owns 53,560 shares of the biopharmaceutical company’s stock valued at $2,829,000 after buying an additional 6,000 shares in the last quarter. AlpInvest Partners B.V. purchased a new stake in shares of Agios Pharmaceuticals during the second quarter valued at approximately $1,257,000. Emerald Acquisition Ltd. purchased a new stake in shares of Agios Pharmaceuticals during the second quarter valued at approximately $319,000. Finally, BlackRock Advisors LLC raised its stake in shares of Agios Pharmaceuticals by 1,942.6% in the second quarter. BlackRock Advisors LLC now owns 253,023 shares of the biopharmaceutical company’s stock valued at $10,600,000 after buying an additional 240,636 shares in the last quarter. Institutional investors own 89.43% of the company’s stock.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded up 1.10% on Friday, reaching $41.24. The company’s stock had a trading volume of 402,026 shares. The stock’s 50 day moving average is $44.28 and its 200-day moving average is $47.50. Agios Pharmaceuticals, Inc. has a 52 week low of $33.50 and a 52 week high of $67.74. The firm’s market capitalization is $1.73 billion.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.52) by $0.11. Agios Pharmaceuticals had a negative net margin of 341.56% and a negative return on equity of 53.39%. The company had revenue of $8.98 million for the quarter, compared to the consensus estimate of $7.82 million. During the same quarter last year, the business earned ($1.07) earnings per share. Agios Pharmaceuticals’s quarterly revenue was up 63.9% on a year-over-year basis. Analysts predict that Agios Pharmaceuticals, Inc. will post ($5.23) EPS for the current year.
AGIO has been the subject of several research analyst reports. Oppenheimer Holdings, Inc. initiated coverage on Agios Pharmaceuticals in a research note on Tuesday, November 29th. They set a “market perform” rating for the company. Canaccord Genuity reiterated a “buy” rating and issued a $90.00 target price on shares of Agios Pharmaceuticals in a research note on Monday, December 5th. Zacks Investment Research lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 5th. Cowen and Company reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Monday, January 9th. Finally, CIBC upgraded Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 17th. Five analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $62.70.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).